Verapamil therapy for unstable angina pectoris: review of double-blind placebo-controlled randomized clinical trials.
The effectiveness of verapamil in the management of patients with unstable angina pectoris associated with obstructive coronary artery disease was evaluated in 2 double-blind placebo-controlled randomized clinical trials. In the 1st study, verapamil was compared with placebo using alternating 48 hour treatment periods in a multiple cross-over protocol. Verapamil was superior to placebo in abolishing symptomatic and asymptomatic ischemic episodes; there were 127 ischemic events during treatment with placebo but only 27 episodes during therapy with verapamil (p less than 0.006). In the 2nd study, verapamil and placebo were compared using a double-blind randomized parallel design in which the choice of drug was altered and the doses administered were increased according to the individual responses. Verapamil reduced anginal attacks in 12 of 13 patients, but placebo was effective in only 1 of 6 (p less than 0.025); verapamil reduced daily anginal attacks from 3.2 to 0.6/day (p less than 0.01). Thus, verapamil is highly effective in the short-term management of patients with unstable angina secondary to coronary artery disease.
D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy* / Q000209:etiology; D001157:Arterial Occlusive Diseases / Q000150:complications; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000150:complications; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use; D010919:Placebos; D011897:Random Allocation; D014700:Verapamil / Q000009:adverse effects / Q000627:therapeutic use*
D010919:Placebos; D014700:Verapamil; D009543:Nifedipine